CNTX - Context Therapeutics Inc
IEX Last Trade
2.46
0.010 0.407%
Share volume: 27,021
Last Updated: Fri 30 Aug 2024 09:58:23 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.45
0.01
0.41%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.81%
1 Month
15.49%
3 Months
23.00%
6 Months
106.72%
1 Year
127.86%
2 Year
28.13%
Key data
Stock price
$2.46
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.77 - $2.75
52 WEEK CHANGE
$1.46
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: http://www.contexttherapeutics.com/
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.contexttherapeutics.com/
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.
Recent news